JAMA Neurology-Tiantan Hospital’s new discovery: For moderate ischemic stroke, there is no difference in the effect of ticagrelor and aspirin combined with aspirin alone

Dual antiplatelet therapy (DAPT) is a key strategy for early treatment of minor non-myocardial infarction ischemic stroke and transient ischemic attack (TIA)

In an exploratory subgroup analysis of the THALES trial, Wang Yongjun of Capital Medical University and others described the effectiveness of DAPT with ticagrelor plus aspirin in patients with acute ischemic stroke with a baseline NIHSS score of 4 or 5 in the first 30 days And safety

Patients took ticagrelor (180 mg loading dose on day 1 and 90 mg twice daily on days 2 to 30) or placebo within 24 hours of the onset of symptoms

Main clinical outcome: The main outcome is the time to stroke or death within 30 days

Among patients with moderate stroke, 8 patients (0.

In this large-scale study, it was found that compared with patients with less severe ischemic stroke, patients with moderate ischemic stroke benefited from ticagrelor plus aspirin and aspirin alone , while intracranial hemorrhage or other There is no further increase in the risk of serious bleeding events